CURRENT STATUS OF THE CLAIMS

to modulate mammalian gamete adhesion.

In the Claims

The following is a marked-up version of the claims with the language that is underlined ("___") being added and the language that contains strikethrough ("——") being deleted:

- (Original) A pharmaceutical composition comprising:
 a polypeptide comprising at least one discoidin/C domain in an amount effective
- 2. (Original) The composition of claim 1, wherein the polypeptide further comprises at least one EGF domain.
- 3. (Currently Amended) The composition of <u>claim 1</u> elaims 1 or 2, further comprising a pharmaceutically acceptable carrier or excipient.
- 4. (Currently Amended) The composition of <u>claim 1</u> <u>claims 1-3</u>, wherein the polypeptide competitively inhibits in vivo or in vitro binding of sperm to unfertilized zona pellucida.
- 5. (Currently Amended) The composition of claim 1, wherein the polypeptide promotes in vivo or in vitro binding of sperm to unfertilized zona pellucida.
- 6. (Currently Amended) The composition of <u>claim 1 elaims 1-5</u>, wherein the polypeptide comprises SED1 polypeptide or a fragment thereof.
- 7. (Currently Amended) The composition of <u>claim 1 elaims 1-5</u>, wherein the polypeptide comprises SEQ ID NOs. 2-7 or a fragment thereof.

- 8. (Currently Amended) The composition of <u>claim 1</u> <u>claims 1-7</u>, wherein the compound binds to male gametes, female gametes, male and female gametes, zona pellucida, or combinations thereof.
- 9. (Original) A recombinant polypeptide comprising SEQ ID Nos. 2-7 or a fragment thereof, wherein the recombinant polypeptide modulates mammalian gamete adhesion.

10-42. (Canceled)

- 43. (Newly Added) The composition of claim 2, further comprising a pharmaceutically acceptable carrier or excipient.
- 44. (Newly Added) The composition of claim 2, wherein the polypeptide competitively inhibits in vivo or in vitro binding of sperm to unfertilized zona pellucida.
- 45. (Newly Added) The composition of claim 3, wherein the polypeptide competitively inhibits in vivo or in vitro binding of sperm to unfertilized zona pellucida.
- 46. (Newly Added) The composition of claim 4, wherein the polypeptide competitively inhibits in vivo or in vitro binding of sperm to unfertilized zona pellucida.
- 47. (Newly Added) The composition of claim 2, wherein the polypeptide comprises SED1 polypeptide or a fragment thereof.
- 48. (Newly Added) The composition of claim 4, wherein the polypeptide comprises SED1 polypeptide or a fragment thereof.
- 49. (Newly Added) The composition of claim 2, wherein the polypeptide comprises SEQ ID NOs. 2-7 or a fragment thereof.

- 50. (Newly Added) The composition of claim 4, wherein the polypeptide comprises SEQ ID NOs. 2-7 or a fragment thereof.
- 51. (Newly Added) The composition of claim 2, wherein the compound binds to male gametes, female gametes, male and female gametes, zona pellucida, or combinations thereof.
- 52. (Newly Added) The composition of claim 4, wherein the compound binds to male gametes, female gametes, male and female gametes, zona pellucida, or combinations thereof.